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Abstract
Herpesviruses have evolved numerous immune evasion strategies to facilitate establishment of lifelong persistent
infections. Many herpesviruses encode gene products devoted to preventing viral antigen presentation as a means of
escaping detection by cytotoxic T lymphocytes. The human herpesvirus-7 (HHV-7) U21 gene product, for example, is an
immunoevasin that binds to class I major histocompatibility complex molecules and redirects them to the lysosomal
compartment. Virus infection can also induce the upregulation of surface ligands that activate NK cells. Accordingly, the
herpesviruses have evolved a diverse array of mechanisms to prevent NK cell engagement of NK-activating ligands on virus-
infected cells. Here we demonstrate that the HHV-7 U21 gene product interferes with NK recognition. U21 can bind to the
NK activating ligand ULBP1 and reroute it to the lysosomal compartment. In addition, U21 downregulates the surface
expression of the NK activating ligands MICA and MICB, resulting in a reduction in NK-mediated cytotoxicity. These results
suggest that this single viral protein may interfere both with CTL-mediated recognition through the downregulation of class
I MHC molecules as well as NK-mediated recognition through downregulation of NK activating ligands.
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Introduction
Human herpesvirus-7 (HHV-7) is a T-lymphotrophic beta-
herpesvirus, most closely related to human herpesvirus-6 (HHV-6)
and human cytomegalovirus (HCMV). HHV-6 and -7 share many
biological properties: HHV-6 and -7 possess genomes that are
almost entirely colinear, and both HHV-6 and -7 can cause the
formation of giant multinucleated cells in culture, features
reminiscent of those seen in HCMV infection in vitro. Primary
infection with either of these viruses results in a short febrile illness,
and more than 90% of adults are seropositive for both HHV-6 and
HHV-7 [1].
Like all herpesviruses, HHV-7 remains latent or establishes
persistent lifelong infections in its host. In so doing, herpesviruses
have evolved numerous strategies to evade immune detection.
Most herpesviruses, including HHV-7, have evolved mechanisms
to interfere with viral antigen presentation by class I MHC
molecules (for review see [2–4]). Although preventing surface
expression of class I MHC molecules may be an effective means of
escaping CTL detection, the absence of class I products from the
cell surface may render the host cell susceptible to Natural Killer
(NK) cell attack (for review, see [5]).
Activation of NK cells is regulated by the balance of inhibitory
and activating signals received through cell surface NK receptors
(for review, see [6,7]). NK inhibitory receptors bind to classical
and non-classical class I MHC molecules. NK activating receptors
bind to NK activating ligands, some of which are structurally
similar to class I MHC molecules. When an NK cell encounters a
potential target cell, it is thought to integrate the activating and
inhibitory signals it receives; if activating signals prevail, the NK
cell can then directly kill its target. In response to microbial
infection or other cell stressors, cells can increase the surface
expression of NK activating ligands, improving the likelihood that
NK cells recognize and kill cells that become harmful. Viral
strategies to remove inhibitory ligands (class I MHC molecules)
from the cell surface of an infected cell might further skew the
balance in favor of NK killing. Not surprisingly, viruses have also
evolved counter-strategies to interfere with NK engagement (for
review, see [8,9]). For example, presumably to escape NK
detection, several viruses selectively downregulate HLA-A and
HLA-B locus products, while leaving HLA-C, -E, and other non-
classical class I MHC molecules at the plasma membrane as
inhibitory ligands for NK cell receptors (for review, see [5,10]).
In addition to the selective downregulation of NK-inhibitory
HLAmolecules, another strategyemployedby viruses to escapeNK
engagement is the downregulation of NK activating ligands from
the cell surface. For example, the HCMV immunoevasin UL16 was
found to bind totwomembers ofa family of cellularproteinstermed
UL16-binding proteins, or ULBPs [11]. UL16 was also found to
associatewitha protein called MICB, forMHCclass I chain-related
protein family [11]. Both the MICs and the ULBPs are activating
ligands for the same NK activating receptor, NKG2D, and both
MICs and ULBPs share structural similarity with class I MHC
molecules (see schematic depicting the general structure of these
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ULBP2, ULBP6 (RAET1L) and MICB and retains these activating
ligands intracellularly, reducing NK recognition of HCMV-infected
cells [15–18]. Indeed, the NKG2D ligands are frequent targets of
viral immunoevasins, underscoring the importance of these ligands
in anti-viral immunity. Both murine and human cytomegaloviruses
encode multiple immunoevasins that affect NK activating ligands.
In addition to UL16, HCMV UL142 retains MICA in the Golgi
[19], and MCMV m145, m152, and m155 impair the cell surface
expression of murine NKG2D ligands [20–23]. Adenovirus E3/
19K can also sequester MICA and MICB intracellularly [24], and
the KSHV K5 ubiquitin ligase promotes the degradation of MICA
and MICB [25,26]. In addition, HCMV, KSHV, and EBV all
encode microRNAs that target MICB mRNA, reducing its
expression [27].
We have shown previously that HHV-7 encodes a gene product,
U21, that can associate with and affect the surface expression of all
classical class I MHC gene products (HLA-A, -B, and -C) by
rerouting them to lysosomes, where they are degraded [28]. U21
can also bind to and downregulate the non-classical class I MHC
gene products (HLA-E and -G)[28]. Such a comprehensive
downregulation of NK-inhibitory class I molecules should shift the
balance of ligands toward one that would activate NK cells, alerting
them to HHV-7 infection. For HHV-7 to succeed, then, it must also
encode a means to escape engagement by NK cells.
Because U21 can associate with and affect the surface
expression of such a wide variety of class I MHC gene products,
we hypothesized that U21 might also affect the structurally-related
activating NKG2D ligands. Class I MHC molecules are composed
of three domains, a1, a2, and a3, and they assemble with a light
chain, b2-microglobulin (b2m), and peptide. Like class I MHC
molecules, MICA and MICB are also type I membrane proteins
that contain a1, a2, and a3 domains, but they do not associate
with b2m or peptide (see schematic, Figure 1, panel A) [29,30].
The NKG2D ligands share structural homology, but little amino
acid identity with class I MHC molecules; MICA, for example,
shares an average of only ,29% amino acid identity with the
HLA-A2 class I heavy chain [11]. The ULBP proteins possess a1
and a2 domains, but lack an a3 domain, and rather than
transmembrane domains, ULBP1–3 are GPI-anchored proteins
[11].
Here we show that U21 can associate with the NKG2D ligand
ULBP1 and redirect it to lysosomes for degradation. U21 can also
reduce the surface expression of two other NKG2D ligands,
MICA and MICB, resulting in protection from NK cytotoxicity.
Results
U21 reduces the surface expression of MICA and MICB
Constitutive levels of NKG2D ligands are low in most cells,
thus, to examine the effect of U21 upon the surface expression of
the NK ligands, we generated U373 astrocytoma cell lines
individually stably expressing ULBP1, ULBP2, ULBP3, MICA,
or MICB, using retrovirus-mediated gene transfer. We then stably
expressed U21 in each of the NK-ligand-expressing cell lines. Each
cell line expressed similar levels of U21, as assessed by immunoblot
(Figure 1, panel B). We next investigated the effect of U21
expression on the surface expression of each NKG2D ligand using
flow cytometry. U21 expression resulted in a slight downregulation
of ULBP1 and ULBP3 from the cell surface, while surface levels of
ULBP2 were essentially unchanged (Figure 1, panels C - E,
compare light gray shaded traces to black traces). The NK ligands
MICA and MICB, however, were more markedly reduced by U21
(Figure 1, panels F and G). Similar results were seen in U21-
expressing K562 cells, as discussed later.
U21 also binds to and reroutes class I MHC molecules to
lysosomes, reducing their presence at the cell surface. When we
examined U21’s effect upon the surface expression of endogenous
class I MHC molecules in each of the NK ligand-expressing cell
lines, endogenous class I molecules were more effectively
downregulated by U21 than were any of the NK ligands
(Figure 1, panels H-L, compare light gray shaded traces to black
traces). Of note, the surface expression of endogenous class I
MHC molecules is similarly affected in each of the cell lines, with
the majority of U21-expressing cells showing reduced surface class
I levels, and a smaller population of cells exhibiting normal surface
levels of class I molecules. This broad distribution reflects the
variable levels of U21 expression among individual cells; in
general, we find that cells expressing higher levels of U21 possess
less class I MHC, ULBP1, or MIC on their cell surface (Figure S1).
The similar pattern of surface class I MHC downregulation within
each population of cells serves as a second, indirect measure of the
similar levels of U21 expression in each of the stable cell lines.
These results suggest that, in addition to class I MHC molecules,
U21 may also impair the surface expression of the NKG2D
ligands MICA and MICB. To a far lesser extent, U21 affects the
surface expression of the ULBPs.
U21 redirects ULBP1 to a lysosomal compartment
U21 expression results in a dramatic steady-state redistribution
of class I MHC molecules from the cell surface to the lysosomal
compartment (Figure 2, panels A and B). Although U21
accompanies class I MHC molecules to lysosomes, and both
molecules are degraded there, U21 does not colocalize with class I
MHC molecules in lysosomes [30]. Instead, U21 is localized in the
ER/Golgi (Figure 2, panel C, [31,32]). Explanations for this
phenomenon include the possibility that U21 may be more
sensitive to lysosomal proteases, such that we are not able to
visualize a concentration of U21 in lysosomes. However,
incubation in lysosomal protease inhibitors does not significantly
alter the steady-state distribution of U21. It is possible the epitopes
recognized by our antibodies, all located within the cytoplasmic
tail of U21, may become masked upon U21’s arrival in lysosomes,
Author Summary
The long coevolution of herpesviruses with their hosts has
resulted in the development of a diverse array of viral
immune evasion strategies and host counter-strategies.
The identification of viral proteins that impair the function
of cellular immune-recognition receptors has proven fertile
ground for the discovery of fundamental concepts in
immunology and cell biology. While the cytomegalovirus-
es have demonstrated an extraordinary array of immu-
noevasive tactics, little is known about the immunoevasive
strategies of the closely-related human herpesvirus-7
(HHV-7). We have previously demonstrated that the U21
gene product from HHV-7 likely interferes with viral
antigen presentation to cytotoxic T cells by rerouting class
I major histocompatibility molecules to lysosomes for
degradation. In addition to the host’s cytotoxic T cell
response, virus infection also induces the expression of
Natural-Killer (NK) activating ligands, alerting cytotoxic NK
cells to identify and kill virus-infected cells. Here we
describe a novel function for the same viral protein - U21 -
in interfering with NK cell recognition. Our findings
provide the first indication that HHV-7, too, may have
found it necessary to strategize mechanisms of NK escape.
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most likely is the possibility that U21 exists in far greater
abundance in the ER and Golgi, such that we cannot see U21
in lysosomes over the brilliant ER/Golgi labeling. We have
previously discussed this differential localization of U21 with its
client class I MHC molecules in greater detail [30].
Because U21 reduced the surface expression of ULBP1,
ULBP3, MICA, and MICB, we next assessed whether expression
of U21 might lead to relocalization of the NK ligands within the
cell, just as it does for class I MHC molecules. Like endogenous
class I MHC molecules, in the absence of U21, the NK-ligands
were localized primarily on the plasma membrane, with some
labeling of the Golgi, as the molecules traverse the biosynthetic
pathway (Figure 2, left panels). U21 expression did not result in
appreciable relocalization of ULBP2 and ULBP3, (Figure 2,
panels G-L), even though U21 expression resulted in slight
reduction of ULBP3 surface expression (Figure 1, panel E). MICA
and MICB, on the other hand, seemed to disappear in cells
expressing U21 (Figure 2, panels N,O and Q,R asterisks). In cells
expressing U21 (Figure 2, panel F), ULBP1 was relocalized to a
punctate compartment resembling U21-relocalized class I MHC
molecules (Figure 2, compare panels E (asterisks) to B).
Redistribution of ULBP1 molecules correlated with the level of
U21 expression in the cell; in Figure 2, panels E and F show a
population of cells exhibiting heterogeneous expression of U21. In
cells with intense U21 labeling (asterisks), ULBP1 punctae are
more readily apparent. We therefore examined whether ULBP1 in
U21-expressing cells was localized in a lysosomal compartment.
Double-label immunofluorescence microscopy showed colocaliza-
tion between ULBP1 and the lysosomal membrane protein lamp2
in U21-expressing cells (Figure 3).
U21 binds to ULBP1 and redirects it to lysosomes for
degradation
In cells expressing U21, class I MHC molecules are degraded in
a lysosomal compartment [32]. Since the relocalization of ULBP1
resembled the relocalization of class I MHC molecules, we next
asked whether U21 expression also resulted in the lysosomal
degradation of ULBP1, using pulse-chase analysis of ULBP1 in the
presence of lysosomal protease inhibitors. Stabilization of a protein
in the presence of lysosomal protease inhibitors would suggest a
role for lysosomal proteases in the turnover of that protein.
We first performed pulse-chase analysis of ULBP1 in the
absence of U21. After a 15-minute pulse label of ULBP1-
Figure 1. Generation of stable cell lines expressing NK ligands and U21. (A) Schematic representation of class I MHC molecules and NKG2D
ligands, depicting a1, a2, and a3 domains of class I MHC molecules, and their overall structural similarity to MICA/B and ULBP molecules. (B) Cell
lysates (20 mg) immunoblotted with an antibody directed against U21 or GAPDH, as indicated. Flow cytometric analysis of U373 cells expressing NK
ligands or NK ligands and U21. Cells were labeled with antibodies directed against (C) ULBP1 (m295), (D) ULBP2, (E) ULBP3, (F) MICA, and (G) MICB
(m360) followed by a PE-conjugated secondary antibody, or with FITC-W6/32 (class I MHC) (H-L). Unlabeled cells (H-L) or cells labeled with the
secondary antibody alone (C-G) are indicated by the filled dark gray trace. Control cells labeled with antibodies directed against each NK ligand (C-G)
or class I MHC molecules (H-L) are indicated by the filled light gray traces. U21-expressing cells labeled with antibodies directed against each NK
ligand (C-G) or class I MHC molecules (H-L) are indicated by the black traces.
doi:10.1371/journal.ppat.1002362.g001
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(Figure 4, panel A, lane 1). At the 2- and 6-hour chase points,
ULBP1 migrated more slowly, at ,37 kDa (Figure 4, panel A,
lanes 2 and 3). ULBP1 possesses a single N-linked glycosylation
consensus site, thus the ,6 kDa increase in ULBP1 at the later
chase points is either the result of additional modifications to its
single predicted N-linked glycan, or possibly O-linked glycosyla-
tion.
Surprisingly, we recovered ,5-fold less labeled ULBP1
immediately following the pulse label (0 hr chase) than after the
2- and 6-hour chase periods (Figure 4, panel A, compare lanes 1 to
2 and 3). One possible explanation for the difference in recovery of
ULBP1 is that the ULBP1 monoclonal antibody can more easily
recognize ULBP1 after it has moved beyond the ER and Golgi;
the immunoprecipitations were performed under non-denaturing
conditions, thus it is possible that the epitope recognized by the
anti-ULBP1 antibody was partially masked while ULBP1 was in
the ER, perhaps as a result of protein complex formation during
addition of the GPI anchor. Protein complex formation during
addition of the GPI anchor might also explain why we observe no
Endo H-sensitive GPI-linked UBLP1 after the pulse label.
Alternatively, antibody recognition may become enhanced by
modifications to the N-linked glycan that occur in the Golgi
compartment or structural changes that occur after addition of the
GPI anchor.
To determine whether the size difference between the two
species of ULBP1 seen in lanes 1 and 2 was solely attributable to
modifications to its predicted N-linked glycan, we digested the
immunoprecipitated proteins with either endoglycosidase H (Endo
H) or peptide N-glycosidase:F (PNGase:F). Endo H cleaves N-
linked glycans found on proteins in the ER and early Golgi.
Glycoproteins that have progressed beyond the medial Golgi
become resistant to digestion with Endo-H, thus resistance to
Endo H can be used to follow the movement of a protein through
the secretory pathway. After the 15 minute pulse label, Endo H
digestion of ULBP1 resulted in a more rapidly migrating
polypeptide of ,28 kDa, consistent with its predicted molecular
weight in the absence of N-linked glycans (Figure 4, panel A,
compare lanes 1 and 4). This Endo H-sensitive form represents
newly-synthesized ULBP1 present in the ER or early Golgi. At the
later chase points, the 37 kDa form of ULBP1 was resistant to
Endo H digestion, suggesting that this form of ULBP1 has
progressed beyond the medial Golgi (Figure 4, panel A, lanes 5
and 6).
PNGase:F cleaves N-linked glycans from all polypeptide chains,
regardless of oligosaccharide processing within the secretory
pathway. After the 15 minute pulse label, PNGase:F digestion of
ULBP1 resulted in a polypeptide of ,28 kDa, co-migrating with
the 28 kDa Endo H-digested form (Figure 4, panel A, compare
lanes 7 and 4). If the slower migration of the 37 kDa form of
ULBP1 were solely the result of N-glycosylation, the mobility of
the products of Endo H and PNGase:F digestion should be the
same – migrating at 28 kDa. Instead, the 37 kDa Endo H-resistant
form of ULBP1 was reduced to a polypeptide of ,31 kDa after
PNGase:F digestion, suggesting a separate post-translational
modification to ULBP1 (Figure 4, panel A, lanes 8 and 9). ULBP1
is a GPI-anchored protein [11]. It is possible that the slower
mobility of ULBP1 may reflect the addition of the GPI anchor.
However, since glypiation occurs in the ER, before glycoproteins
become Endo H-resistant, we should observe the 31 kDa Endo H-
sensitive GPI-linked ULBP1 after the initial pulse label, and we do
Figure 3. ULBP1 colocalizes with the lysosomal marker lamp2.
(A-C) U373 cells expressing ULBP1 and U21 were double-labeled with
antibodies directed against ULBP1 (magenta) and lamp2 (green). The
merged image is shown in panel C. The arrowheads denote single
coincident puncta, and the boxed regions in the bottom right corner of
each panel are enlargements of the smaller boxed region with
arrowhead in panel C.
doi:10.1371/journal.ppat.1002362.g003
Figure 2. U21 reroutes ULBP1 and MICB to a punctate perinuclear compartment. Left panels: U373 cells (A), and U373 cells expressing each
NK ligand and control vector were immunolabeled with antibodies directed against properly-folded class I MHC molecules (W6/32)(A), or against
ULBP1 (m295)(D), ULBP2 (G), ULBP3 (J), MICA (M), or MICB (m360) (P), as noted. Middle and right panels: Cells expressing each NK-ligand and U21, as
indicated, were double-labeled with antibodies directed against class I MHC molecules (B), ULBP1 (E), ULBP2 (H), ULBP3 (K), MICA (N), or MICB (Q) and
anti-U21 (panels C,F,I,L,O, and R). Asterisks in panels E and F denote cells expressing U21 (F) that also exhibit relocalization of ULBP1. Asterisks in
panels N, O, Q, and R indicate cells expressing U21 (O and R) that also exhibit reduced labeling of MICA or MICB. The arrowheads in panels Q and R
denote a cell with low apparent levels of U21 (R) and normal surface expression of MICB.
doi:10.1371/journal.ppat.1002362.g002
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is O-glycosylated.
Having established the normal trafficking of ULBP1 in the
absence of U21, we next performed pulse-chase experiments in
U21-expressing cells. To investigate whether U21 expression
resulted in the destabilization of ULBP1, we performed pulse-
chase experiments in the presence of the lysosomal protease
inhibitor leupeptin, and the vacuolar H
+-ATPase inhibitor
folimycin. In cells lacking U21, ULBP1 appeared stable through-
out the 6 hr chase period, and lysosomal inhibitors did not
significantly increase its stability (Figure 4, panel B, compare lanes
2 and 3 to 5 and 6). In cells expressing U21, however, we
recovered fewer labeled ULBP1 molecules after the 6-hour chase
period, and in the presence of lysosomal inhibitors, ULBP1 was
stabilized (Figure 4, panel B, compare lanes 8 and 9 to 11 and 12).
Quantification of the stabilization of ULBP1 in the presence of
lysosomal protease inhibitors is shown in Figure 4, panel C. We
have shown previously that U21 and class I MHC molecules are
also stabilized in the presence of leupeptin and folimycin [32,33].
To ensure that the effectiveness of our lysosomal protease
inhibitors was comparable to inhibition observed in prior
experiments, we immunoprecipitated U21 molecules from the
same cells, in parallel (Figure 4, panel B, lanes 13–16, compare
lanes 14 and 16). We note that the stabilization of ULBP1 resulting
from U21 expression is not as dramatic as U21-mediated
stabilization of class I MHC molecules. Nonetheless, these results,
and the relocalization of ULBP1 to lysosomes in U21 expressing
cells (Figure 3), suggest that U21 can also reroute ULBP1 to
lysosomes for degradation.
When we recovered U21 from metabolically-labeled ULBP1-
expressing cells, we observed labeled co-precipitating class I heavy
chains, but we did not observe co-precipitating ULBP1 molecules
(Figure 4, panel B, lanes 13–16). Likewise, when we recovered
ULBP1, we observed no labeled coprecipitating U21 molecules
(Figure 4, panel B, lanes 7–12, migration position of U21 is shown
in lanes 13–16). We therefore performed coimmunoprecipitation
experiments using lysis buffer containing digitonin rather than
TritonX-100. Under these conditions, when we recovered U21,
we observed coprecipitation of two polypeptides identical in size to
ULBP1 (Figure 5, panel A, lane 4). In the reciprocal immunopre-
cipitation, however, when we recovered ULBP1 from digitonin
lysates, we failed to observe co-precipitation of U21. It is possible
that the anti-ULBP1 antibody precludes co-precipitation of U21
with ULBP1.
To confirm the identity of the polypeptides coimmunoprecipi-
tating with U21 as ULBP1 molecules, we recovered U21
molecules from cells expressing HA-tagged ULBP1 (Figure S2),
and immunoblotted the immunoprecipitates with an antibody
directed against the HA epitope tag. Because steady-state levels of
proteins destined for the lysosomal compartment can be difficult to
detect, we sought to minimize the lysosomal degradation of U21
and HA-ULBP1 by preincubating the cells in the presence of
lysosomal protease inhibitors. In lysates from digitonin-lysed HA-
ULBP1-expressing cells, we observed both the ER-resident, non-
GPI-linked form of HA-ULBP1, as well as the GPI-linked mature
form, with the mature form predominant (Figure 5, panel B, lanes
1 and 2). When we immunoprecipitated U21 from HA-ULBP1
cells expressing U21, the HA antibody recognized both forms of
HA-ULBP1 in the anti-U21 immunoprecipitation (Figure 5, panel
B, lane 4). Thus, U21 associates with both the ER- and mature
forms of ULBP1 molecules. These results suggest that U21 binds
to ULBP1 in the ER and maintains its association with ULBP1
through the secretory pathway en route to lysosomes.
U21 affects the half-life of MICB and alters its
glycosylation
The localization of the MICA and MICB in U21-expressing
cells is unusual; rather than punctate lysosomal localization, cells
expressing U21 exhibit very little MIC labeling at all (Figure 2,
panels N, O, Q, and R, asterisks). Given the structural similarity
between class I MHC molecules, ULBPs, and the MIC proteins,
we thought it likely that MICA and MICB would also be rerouted
to lysosomes for degradation, and surmised that perhaps the half-
life of the MICs in the lysosomal compartment might be too short
to allow visualization of the MIC proteins in punctae.
We therefore examined the turnover of MICB in the presence
of lysosomal protease inhibitors. Because MICA and MICB share
83% similarity, and because both proteins are similarly affected by
U21, we chose to examine MICB rather than MICA, since in
general, MICB-expressing cells exhibited more dim, yet visible,
punctae than MICA-expressing cells (Figure 2, compare panels N
and Q).
In the absence of U21, after a 15 minute pulse-label, MICB
migrated at a molecular mass of ,60 kDa (Figure 6, panel A, lane
1). MICB became heterogeneously glycosylated (,65–75 kDa)
following a 2-hour chase period (Figure 6, panel A, lane 2), and no
detectable MICB remained after 6 hours of chase (Figure 6, panel
A, lane 3). Unlike class I MHC molecules, the cell surface
expression of MICA and MICB is regulated by metalloproteinase
cleavage, which results in shedding of the soluble extracellular
domains from the cell surface, thus the half-life of MICB is likely
the combined result of cleavage and release of soluble MICB by
metalloproteinases [34–37] and of routine protein turnover [38].
Incubation of the MICB-expressing cells in lysosomal protease
inhibitors resulted in slight stabilization of the MICB molecules
(Figure 6, panel A, lanes 4–6, panel B, MICB), suggesting that
some fraction of MICB is degraded in the lysosomal compartment.
In cells expressing U21, the turnover of MICB molecules was
accelerated (Figure 6, panel A, lanes 7–9, and panel C), suggesting
that, as for ULBP1 and class I MHC molecules, U21 might
function to reroute MICB to the lysosomal compartment for
degradation. However, lysosomal protease inhibitors stabilized
MICB in U21 cells to approximately the same degree as in cells
expressing MICB alone (Figure 6, panel A, lanes 10–12, and panel
B), suggesting that U21 does not enhance the lysosomal
degradation of MICB. To ensure that our lysosomal protease
inhibitors were active, we recovered U21 from the same MICB-
U21-expressing lysates, and found the lysosomal protease
Figure 4. U21 targets ULBP1 for lysosomal degradation. (A) U373 cells expressing ULBP1 were pulse-labeled for 15 minutes and chased for 0,
2, or 6 hours. ULBP1 was recovered from Triton X-100 lysates with anti-ULBP1 (m295) and treated with either Endo H or PNGase:F. Migration of ULBP1
with and without its N-linked glycan are indicated, as is the approximate position of the 36 kDa molecular weight marker. (B) Cells, as indicated, were
pulse-labeled for 15 minutes, chased for 0, 2, and 6 hours and either ULBP1 (m295) or U21 were recovered from Triton X-100 lysates. Where indicated,
cells were treated with leupeptin (leu) and folimycin (foli). Migration of U21, class I MHC heavy chain (MHC I), and mature (ULBP1
mat) and immature
(ULBP1
ER) forms of ULBP1 are indicated, as are the approximate positions of molecular weight markers. (C) As a measure of the stability of ULBP1, the
percentage of ULBP1 remaining after the 6 hr chase was compared to the percentage of ULBP1 remaining after the 2 hr chase point. The data
represent the quantification from three independent experiments (n=3). Error bars indicate the standard deviation.
doi:10.1371/journal.ppat.1002362.g004
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molecules (Figure 6, panel A, lanes 13–18).
Because the half-life of MICB was reduced in U21-expressing
cells, we performed immunoblot analysis to examine the steady-
state levels of MICB. In the absence of U21, we detected three
polypeptides with an anti-MICB antibody (Figure 7, panel A, lane
1). The uppermost band corresponded in size to the mature form
of MICB, and is the predominant form. The middle band
corresponded in size to the immature ER form, and the lower
band corresponded in size to soluble ‘‘shed’’ MICB. Expression of
U21 resulted in a reduction in the steady-state level of MICB,
primarily of the mature form (Figure 7, panel A, lane 2, top
bands), suggesting that U21 expression results in the degradation
of MICB after it has acquired Endo H-resistance, later in the
secretory pathway.
We envisioned two possible explanations for the reduction in
steady-state levels of MICB: U21 might enhance MICB
degradation by either lysosomal or proteasomal proteases.
However, neither lysosomal hydrolases nor proteasomal proteases
appeared to participate appreciably in U21-mediated degradation
of MICB (Figure 6, panels A and B, data not shown). Alternatively,
we hypothesized that U21 might accelerate MICB’s cleavage and
release from the cell, resulting in the appearance of reduced
steady-state levels of MICB. To examine the effect of U21
expression on the amount of secreted MICB in the supernatants,
we examined the steady-state levels of MICB in supernatants of
MICB- and MICB-U21-expressing cells. Rather than elevated
levels of secreted MICB, we found a reduction in the amount of
MICB present in the supernatant of U21-expressing cells, instead
suggesting that U21 impairs the release of MICB (Figure 7, panel
A, lanes 3 and 4).
To further evaluate the effect of U21 on MICB secretion, we
performed a pulse-chase experiment over a shorter 4-hr chase
period, recovering MICB from both lysates and supernatants after
0, 0.5, 1, 2, and 4 hours of chase (Figure 7B). The turnover of
MICB was rapid; after 4 hours, there was very little labeled MICB
recoverable from either control or U21-expressing cell lysates
(Figure 7B, panel i, lanes 5 and 10). To examine shedding of
MICB into the medium, we recovered MICB from the medium by
immunoprecipitation and subjected it to SDS-PAGE. While we
detected labeled secreted MICB in the medium of MICB-
expressing cells (Figure 7B, panel ii, lanes 1–5), we recovered
almost no MICB in the medium of U21-expressing MICB cells
(Figure 7, panel ii, lanes 6–10), further suggesting that U21 impairs
the shedding of MICB into the medium.
In cells expressing U21, the heterogeneously glycosylated
MICB migrated slightly faster than MICB from control cells
(Figure 7B, panel i, compare lanes 4 and 7), suggesting that U21
expression affected the trimming of either the MICB core
polypeptide or its N-linked sugars. To determine whether U21
expression induced a reduction in the core polypeptide size of
MICB, we digested MICB immunoprecipitates with PNGase:F
Figure 5. U21 interacts with ULBP1. (A) U373 and ULBP1-U21 cells were labeled for 2 hrs, and either U21 or ULBP1 (m295) was recovered from
digitonin lysates. Migration positions of U21, class I MHC heavy chain, and ULBP1 are indicated. Arrows indicate potential coimmunoprecipitating
polypeptides identical in size to ULBP1. (B) Cells, as indicated, were incubated in the presence of folimycin and leupeptin, and U21 was recovered
from digitonin lysates. Lysates and immunoprecipitations were immunoblotted with anti-HA and anti-U21 antibodies. Migration positions of mature
(HA-ULBP1
mat) and immature (HA-ULBP1
ER) HA-ULBP1 and U21 are noted.
doi:10.1371/journal.ppat.1002362.g005
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PLoS Pathogens | www.plospathogens.org 8 November 2011 | Volume 7 | Issue 11 | e1002362Figure 6. U21 expression destabilizes MICB. (A) MICB cells or MICB cells expressing U21 were pulse-labeled for 15 minutes and chased for 0, 2,
or 6 hours. MICB (BMO2) and U21 were recovered from Triton X-100 lysates. Migration positions of MICB, U21, and class I MHC heavy chains are
indicated, as are approximate molecular weight markers. Note that U21 and MICB migrate at nearly identical positions. (B) Quantification of (A)
showing the percent MICB remaining after a 2 hr chase relative to the 0 hr chase point (n=1). (C) The data represent the quantification of MICB
stability in MICB or MICB-U21 cells from three independent experiments (n=3). Error bars indicate the standard deviation.
doi:10.1371/journal.ppat.1002362.g006
Figure 7. U21 expression reduces steady state levels of mature and secreted MICB. (A) Immunoblot analysis of lysates or supernatants
from MICB or MICB-U21 cells. Lysates and concentrated supernatants were prepared from 4610
5 MICB or MICB-U21 cells. (B) MICB or MICB-U21 cells
were pulse-labeled for 15 min and chased for 0, 0.5, 1, 2, and 4 hrs. MICB was recovered from Triton X-100 lysates (panel i) or cell supernatants (panel
ii). Migration positions of MICB, soluble MICB (sMICB), and molecular weight markers are indicated. In U21-expressing cells, the faster-migrating
mature (MICB*) and secreted (sMICB*) MICB are noted separately at the right.
doi:10.1371/journal.ppat.1002362.g007
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identical mobility, suggesting that the core polypeptide remained
unchanged, and that the U21-induced increase in MICB mobility
must be the result of altered post-translational modifications to its
N-linked glycans.
U21 reduces sensitivity to NK cell lysis by
down-regulating MICA and MICB
To examine whether the U21-induced downregulation of
surface MICA and MICB could protect cells from NK
recognition, we next performed NK cytotoxicity assays. NK-
Figure 8. U21 down-regulates and destabilizes MICA and MICB in K562 cells. (A-F) Flow cytometric analysis of K562 cells expressing
ZsGreen or U21-ZsGreen labeled with antibodies to (A) ULBP1 (m295), (B) ULBP2, (C) ULBP3, (D) MICA, and (E) MICB (m360), or (F) ICAM-1 followed by
a PE-conjugated secondary antibody. Cells labeled with secondary antibody alone are indicated by the filled dark gray trace. Control ZsGreen-
expressing cells are indicated by the filled light gray trace, and ZsGreen-U21 cells are indicated by the black trace. (G-I) Cells were fixed,
permeabilized, and labeled with antibodies directed against (G) MICA, (H) MICB (m360), or (I) TfR. Cells labeled with secondary antibody alone are
indicated by the filled dark gray trace. Control ZsGreen-expressing cells are indicated by the filled light gray trace, and ZsGreen-U21 cells are indicated
by the black trace.
doi:10.1371/journal.ppat.1002362.g008
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to both inhibitory and activating ligands. Since U21 affects both
class I MHC molecules (NK inhibitory ligands) and the MIC
proteins (NK activating ligands), analysis of NK cytoxicity toward
U21-expressing cells is complicated. To simplify the assessment of
U21’s effect upon MICA and MICB, we expressed U21 in the
erythroleukemic cell line K562, which lack class I MHC
molecules, thus any effect of U21 on NK cytotoxicity toward
K562 cells should be independent of U21’s ability to downregulate
the surface expression of class I MHC molecules.
For these cytotoxicity assays, we generated a population of
K562 cells stably expressing U21 (See Figure S4). When we
examined the surface expression of the endogenous NKG2D
ligands in the U21-expressing K562 cells, similar to our results in
U373 cells, we observed a very slight decrease in the surface
expression of endogenous ULBP1 in the U21-expressing K562
cells (Figure 8, panel A), and an even more prominent decrease in
the surface expression of MICA and MICB (Figure 8, panels D
and E). Surface levels of endogenous ULBP2 also appeared slightly
reduced in the K562 cells, while the endogenous surface ULBP3
appeared to be unaffected (Figure 8, panels B and C), as was the
surface expression of ICAM-1, an adhesion molecule critical for
synapse formation between the NK and target cell (Figure 8, panel
F) [39] (for review see [40]).
To further investigate whether the effects of U21 expression
upon MICB were similar in both K562 and U373 cells, we also
examined the half-life of MICB in the U21-expressing K562 cells.
Because MICB expression in K562 cells is inherently low, we were
unable to detect endogenous MICB by immunoblotting. We
therefore performed intracellular labeling of MICA or MICB,
comparing MIC expression levels using flow cytometry. Steady-
state levels of MICA and MICB were reduced in K562 cells
expressing U21 (Figure 8, panels G and H), suggesting that U21
expression can also result in the destabilization of MICA and
MICB in K562 cells. In contrast, steady state levels of ICAM-1
(data not shown) or the transferrin receptor remained unaffected
by U21 expression in these cells (Figure 8, panel I).
To evaluate the sensitivity of the U21-expressing K562 cells to
NK cytotoxicity, we incubated the target K562 cells in the
presence of effector NKL cells, and determined NK cell
cytotoxicity using a flow cytometric assay. While control K562
cells were sensitive to NK cytotoxicity, cells expressing U21 were
resistant to NK lysis (Figure 9, panel A). U21-expressing cells were
also resistant to NK cytotoxicity from peripheral blood mononu-
clear NK cells (Figure S5).
Figure 9. Expression of U21 in K562 cells reduces sensitivity to
NKL-mediated cytotoxicity. (A) NK cytotoxicity assay. Target K562
cells expressing ZsGreen or U21-ZsGreen were incubated in the
presence of NKL effector cells at the indicated E:T ratios. The graphs
shown are single representative experiment done in triplicate and the
error bars indicate the standard deviation between replicate samples
(n=1). (B-C) Target K562 cells expressing ZsGreen (B) or U21-ZsGreen
(C) as indicated were incubated with 10 mg/ml IgG1 directed against,
MICA, MICB (m360), or a combination of anti-MICA and anti-MICB, or no
antibody (control) before addition of NKL effector cells at the indicated
E:T ratios. The graphs shown are a single representative experiment
performed in triplicate. Error bars indicate the standard deviation
between the replicate samples (n=1). (D) Compilation and statistical
analysis of data from 3 independent experiments performed in triplicate
(n=3). The antibody blocking experiment was also performed once in
triplicate (n=1) using an antibody directed against ULBP1 (m295) or an
IgG1 isotype control (m479). *pvalue,0.05, **pvalue,0.01,
***pvalue,0.001.
doi:10.1371/journal.ppat.1002362.g009
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K562 cells from NKL cytotoxicity, we performed NK cytotoxicity
assays in the presence of blocking antibodies directed against
MICA, MICB, and ULBP1. In control K562 cells, NK
cytotoxicity was reduced by 15% in the presence of an antibody
directed against MICA, by 25% in the presence of an antibody
directed against MICB, and by 80% in the presence of both
antibodies (Figure 9, panel B and D). This synergistic effect in the
presence of blocking antibodies to both MICA and MICB suggest
that the signal for NKL activation can be mediated through either
ligand when one is unavailable, but when both are blocked, target
cells are not able to activate the NKL cells. In contrast, pre-
incubation of the K562 cells with an antibody directed against
ULBP1 or an isotype control had no effect on cytotoxicity
(Figure 9, panel D). Thus, the majority of NKL cytotoxicity
between NKLs and K562 cells is likely mediated through
engagement of MIC proteins on the surface of the target K562
cell with NKG2D on the NKL cells.
Blocking of both MICA and MICB on control K562 cells
reduced the cytotoxicity to a level similar to that seen for U21-
expressing K562 cells (Figure 9, panel C). Unlike control K562
cells, the cytotoxicity toward U21-expressing K562 cells was not
further reduced by pre-incubation with antibodies directed against
MICA or MICB (Figure 9, panel C). Since NKL-mediated
cytotoxicity of K562 cells is largely mediated through MICA and
MICB, the ability of U21 to reduce the surface expression of
MICA and MICB likely contributes significantly to the mechanism
by which U21 protects K562 cells from NK cytotoxicity.
If U21 can bind to and reroute ULBP1 molecules to the
lysosomal compartment in U373 cells overexpressing ULBP1, why
are endogenous ULBP1 surface levels in K562 cells only
minimally reduced by U21, and why does ULBP1 seem to play
no appreciable role in NK cytotoxicity toward K562 target cells?
One possibility to explain the lack of NKL-mediated cytotoxicity
through ULBP1 in the K562 cells may be the relative level of
surface-expressed ULBP1 and its affinity for NKG2D. To explore
the possibility that the surface expression of ULBP1 is insufficient
to provide ligand for NKG2D, we overexpressed the ULBP1
activating ligand in K562 target cells. When ULBP1 was
overexpressed, we observed an increase in NK cytotoxicity toward
ULBP1 expressing cells (data not shown). We conclude that the
constitutively-expressed ULBP1 on the surface of K562 cells may
not be sufficient to induce NKL-mediated killing through
engagement of NKG2D. ULBP1-expressing U373 cells, on the
other hand, express abundant ULBP1, yet U21 has little effect
upon the surface expression of ULBP1 in these cells. We therefore
also think it likely that the affinity of U21 is lower for ULBP1 than
for MICA and MICB. U21 does not act upon ULBP1 as
effectively as it acts upon the MICs and class I MHC molecules.
Discussion
HHV-7 U21 has long been known to bind to and reroute class I
MHC molecules to the lysosomal compartment, likely providing
HHV-7 a means of escaping detection by CTLs (2001). We have
now demonstrated that U21 can reduce NK-mediated cytoxicity
as well, by affecting surface expression of the NKG2D ligands
MICA and MICB.
The MIC proteins are structurally similar to class I MHC
molecules, and U21 expression resulted in the reduced surface
expression of both the MICs and class I MHC molecules, thus we
surmised that U21 acts upon the MICs and class I MHC
molecules in a similar manner. However, we were unable to
demonstrate association between U21 and the MIC molecules.
Moreover, the MICs do not seem to be intensely localized to
lysosomes in U21-expressing cells, nor is their stabilization by
lysosomal protease inhibitors increased upon U21 expression.
Why this difference? It is possible that U21 acts differently upon
MICs than upon class I MHC molecules. Alternatively, the
reagents available to detect the MIC molecules may not be
sufficient to follow the MIC molecules as they traffic to lysosomes.
The MIC family of NKG2D ligands is highly regulated. MIC
expression at the transcriptional level is upregulated in response to
stressors such DNA damage, autoimmunity, and infection (For
review, see [41]). In cells that express MIC proteins, the trafficking
of the MICs is also complex; MIC expression at the cell surface is
regulated both by internalization and recycling, as well as by
shedding of the MIC molecules into the medium [34,37,38].
Perhaps because of the relative complexity of the trafficking of
MIC molecules, U21’s molecular impact upon the MIC molecules
is less straightforward.
Unlike class I molecules, even in the absence of U21, MICB is
partially stabilized by lysosomal protease inhibitors. If U21
functioned to enhance the routing of MICB to lysosomes, we
would have expected to observe enhanced stabilization of MICB
by lysosomal protease inhibitors, but we did not (Figure 6). We
therefore reasoned that if the MICB that disappears during the
chase period is not degraded in lysosomes, then it must be shed or
released from the cell. In control MICB-expressing cells, this
indeed appears to be the case. In cells expressing U21, however,
MICB appears to be neither degraded in lysosomes nor released
into the supernatant (Figure 7). We can think of two possibilities to
explain these observations: either MICB is shed, but the MICB
shed from U21-expressing cells is less stable, explaining why we
are unable to recover it from the medium, or, perhaps MICB
interacts with U21 within the cell, rendering it undetectable by
MICB antiserum. We also found that U21 expression resulted in
altered glycosylation of MICB, thus perhaps this altered
glycosylation of MICB may affect its stability upon release into
the extracellular environment. Alternatively, it is possible that
interaction of U21 with MICB precludes its shedding by the
metalloproteases that cleave it [37].
Several similar trafficking studies examining the mechanism for
HCMV immunoevasin UL16-mediated effect upon MICB have
been performed [15,42]. Like U21, UL16 localizes to the ER and
Golgi region [15,42], reduces the cell-surface expression of MICB
[15], and impairs the release of soluble MICB into the medium
[43]. But, as for U21, the complexity of MIC regulation and
trafficking has impeded a clear understanding of how UL16 affects
MICB trafficking [15,42,43].
The experiments described herein also illuminate some of the
mechanistic and structural aspects of the interaction between U21
and class I MHC molecules: the discovery that U21 binds to the
class I MHC-like ULBP1 contributes to our understanding of
U21’s interaction with class I MHC and class I-like molecules.
U21 can associate with a wide range of class I MHC molecules,
including HLA-A, -B, -C, -E, -G, and even murine class I MHC
molecules [28,32]. The greatest degree of conservation among all
of these class I molecules exists within the a3 domain of these
proteins, thus we originally hypothesized that the a3 domain was
an important structural feature for association of U21 with these
molecules [28] (see schematic, Figure 1, panel A). Interestingly,
ULBP1 possesses a1 and a2 domains, but lacks an a3 domain.
The structural similarities between class I MHC molecules and
ULBP1 would therefore suggest that the binding of U21 to class I
molecules involves the a1 and/or a2 domains.
U21 expression also results in the relocalization of ULBP1 to
lysosomes. However, when U21 is expressed in a cell line that
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the choice is clear: U21 has a more striking affect upon class I
MHC molecules than upon ULBP1, suggesting that U21 may
possess greater affinity for class I MHC molecules than for
ULBP1. It is important to note, however, that our experiments
were performed in cells exogenously overexpressing ULBP1, or in
K562 cells, which express low constitutive levels of ULBP1. In the
context of an HHV-7 infection, it is possible that the relative
expression of ULBP1 and class I MHC molecules may be such
that U21 can act effectively upon ULBP1 molecules. However,
when comparing the effect of U21 upon all of the NKG2D
ligands, it is clear that U21 expression causes a much greater
reduction in the cell surface expression of the MIC molecules than
of the ULBPs, suggesting that U21’s primary effect may be upon
the MIC molecules.
U21’s true utility as an immunoevasin during HHV-7 infection
is, as yet, difficult to assess, because a bacterial artificial
chromosomal system to facilitate genetic manipulation of the viral
genome has not yet been established, and HHV-7 is a human
herpesvirus for which there is no animal model. Additionally,
although HHV-7 is known to infect T cells, the site of infection
where immune escape is most critical for the virus is not certain;
HHV-7 is shed in the saliva of healthy individuals, thus salivary
glands may be a site of persistent infection where evasion of NK
cytotoxicity is essential. It is also possible that, as for closely-related
rhesus CMV, immunoevasin involvement in the escape of immune
detection is important not during primary infection, but during
superinfection with other strains [44].
HHV-7 U21 can bind to and affect the surface expression of
many different HLA class I alleles, including the NK-inhibitory
ligands HLA-C and HLA-E, downregulation of which, in
principle, should render the cell susceptible to NK attack. We
had therefore hypothesized that HHV-7 must encode other means
of NK cell evasion [28]. We now demonstrate that HHV-7 U21
also reduces the surface expression of the NK activating ligands
MICA and MICB, thereby preventing NK cytoxicity toward U21-
expressing cells. Thus HHV-7, through a single viral protein,
encodes a means to escape both CTL and NK cell detection.
Interestingly, like U21, at least two other viral proteins can affect
both CTL and NK cell recognition. The murine CMV m152 gene
product (gp40) causes retention of both class I MHC molecules
and NKG2D-ligands in the endoplasmic reticulum-Golgi inter-
mediate compartment [21,22,45]. Additionally, unlike MCMV,
which encodes multiple means of affecting both CTL and NK
detection, Adenovirus is known to encode only one polypeptide,
E3/19K, which can influence both CTL and NK recognition. E3/
19K binds to class I MHC molecules and to MICA and MICB
molecules and retains them in the ER [24,46,47]. Thus, MCMV
gp40, Adenovirus E3/19K, and HHV-7 U21 all recognize
multiple structurally-similar class I MHC and class I MHC-like
molecules and may possess dual function during viral infection.
Materials and Methods
Cell lines
U373 and HEK293T were cultured in Dulbecco’s modified
Eagle medium (DMEM) supplemented with 5% newborn calf
serum (NCS) and 5% fetal bovine serum (FBS) in the presence of
puromycin (375 ng/ml) (Sigma-Aldrich, St. Louis, MO) or
geneticin (G418) (500 ng/ml)(Invitrogen, Carlsbad, CA), as
needed. K562 cells were cultured in RPMI supplemented with
10% FBS. NKL cells (generously provided by Dr. M. J.
Robertson, Indiana University) were cultured in RPMI supple-
mented with 10% heat-inactivated FBS, 1 mM sodium pyruvate
and 50–100 U/ml IL-2. U373 cells stably expressing the NKG2D
ligands ULBP1, ULBP2, or ULBP3, or MICA or MICB were
generated by retroviral transduction using the vector, pLNCX
(Clontech, Mountain View, CA). In some cases, clones were
isolated to generate cell lines with homogeneous expression of the
NK activating ligand. These cell lines were then transduced with a
lentiviral vector, pHAGE-puro-MCS (PPM)-U21, in which U21
was expressed under the control of a CMV promoter, and an
IRES-driven puromycin N-acetyl transferase gene (Pac) allowed
for puromycin selection [48]. K562 cells stably expressing U21
were generated by lentiviral transduction using a vector identical
to PPM but containing the gene for Zs-Green instead of the Pac
gene (PMG) [48]. The multiple cloning site (MCS) and puromycin
cassette were modifications made to the pHAGE vectors in our
laboratory, where we excised the gene for ZsGreen and replaced it
with the puro cassette. The MCS was inserted in place of the gene
for Ds-Red.
Antibodies
Monoclonal antibodies to ULBP1 (m295, IgG1), ULBP2 (m311,
IgG1), ULBP3 (m551, IgG1) ULBP4 (m479, IgG1), MICA (m673,
IgG1), and MICB (m360, IgG1) were generously provided by
Amgen (Thousand Oaks, CA). Affinity purified goat polyclonal
antibodies directed against ULBP1 (AF1380) and MICB (AF1599)
were purchased from R&D systems (Minneapolis, MN). BMO2, a
monoclonal antibody directed against MICB, was purchased from
Axxora (San Diego, CA). The anti-lamp2 monoclonal antibody
H4B4 was generously provided by Dr. T. August (Johns Hopkins
Medical School, Baltimore, MD). The transferrin receptor (TfR)
monoclonal antibody, (anti-CD71) (clone H68.4) was purchased
from Zymed Laboratories (San Francisco, CA). Monoclonal anti-
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was pur-
chased from Imgenex (San Diego, CA). The intercellular adhesion
molecule-1 (ICAM) monoclonal antibody (anti-CD54) was pur-
chased from BD Biosciences. W6/32 is a monoclonal antibody
that recognizes properly-folded class I MHC molecules [49].
HC10 is a monoclonal antibody that recognizes free class I MHC
heavy chains [50]. Fluorescein isothiocyanate (FITC)-conjugated
W6/32 was purchased from eBiosciences (San Diego, CA). HA.11
is a monoclonal antibody directed against hemagglutinin (HA),
and was purchased from Covance (Princeton, NJ). A polyclonal
antibody (MCW50) directed against the cytoplasmic tail of U21
was generated in our laboratory [31].
Construction of retroviral and lentiviral vectors
ULBP1–3, MICA, and MICB were amplified from plasmids
provided by Dr. D. Cosman and cloned in to LNCX using the
primers below. Constructs were verified by DNA sequencing. U21
was subcloned from PPM-U21 into PMG using XhoI and BamHI.
ULBP1: 5’-ATACTCGAGGCCACCATGGCAGCGGCC-
GCCAG
3’-GTCAGGCTTTCATCTGCCAGCTAGAAT-
GAAG
ULBP2: 5’-AGTCTCGAGGCCACCATGGCAGCAGCC-
GCCGC
3’-GTCAAGCTTTCAGATGCCAGGGAGGATG
ULBP3: 5’-AGTCTCGAGGCCACCATGGAGACAG
3’- GTCAAGCTTTCAGATGCCAGGGAGGATG
MICA: 5’-AGTCTCGAGGCCACCATGGGGCTGGGC-
CCGG
3’-GTCAAGCTTCTAGGCGCCCTCAGTGG
MICB: 5’-AGTCTCGAGGCCACCATGGGGCTGGGC-
CGGG
3’-GTCAAGCTTCTAGGTGCCCTCAGTGG
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Packaging, envelope, and vector plasmids were cotransfected
into HEK293T cells using TransIT-293 (Mirus Bio, Madison,
WI). Viral supernatants were harvested at 48–72 hrs, filtered and
either used to infect desired cell lines directly (retroviral
transductions) or concentrated prior to infections (lentiviral
transductions). Lentiviruses were concentrated by ultracentrifuga-
tion for 3 hrs at 4uC at 50,000xg. K562 cells were infected twice
by spinoculation (1000 X g for 2 hr at 30uC) with concentrated
lentiviruses. For G418- and puromycin-resistant constructs, cells
were cultured in selection medium for at least 10 days.
Immunofluorescence microscopy
Cells grown on glass coverslips were washed with PBS, fixed
with 4% paraformaldehyde in PBS, permeabilized with 0.5%
saponin in PBS and 3% BSA, incubated with primary antibodies,
washed and incubated with Alexa488- or 594-conjugated
secondary antibodies (Invitrogen). Colocalization studies
(Figure 3) were performed using a Zenon Alexafluor 488 kit
(Invitrogen) to label anti-lamp2 and the images were deconvoluted
using Auto Quant 3D deconvolution software (Media Cybernetics,
Bethesda, MD).
Flow cytometry
Adherent cells were detached with trypsin or 5 mM EDTA in
PBS prior to labeling. Cells were washed in ice-cold PBS, and
incubated with primary antibodies in 1% bovine serum albumin/
phosphate buffered saline (BSA/PBS) for 30 min on ice. For
nonconjugated primary antibodies the cells were then washed with
1% BSA/PBS and incubated with Goat F(ab)2 Anti-Mouse IgG
(H+L) Phycoerythrin (PE)(R&D Systems, Minneapolis, MN). For
intracellular staining, cells were fixed with 1% paraformaldehyde
(PFA) and permeabilized with 0.1% saponin prior to staining.
Flow cytometry was performed on either a FACSCalibur or
FACSAria III (BD Biosciences), or Guava Easycyte mini
(Millipore, Billerica, MA) and the data was analyzed using FlowJo
software (Treestar, Ashland, OR).
Pulse-chase experiments
Cells were detached with trypsin and incubated in methionine-
and cysteine-free DMEM (Invitrogen) supplemented with 2%FBS
for 30 min at 37uC (starve). The cells were labeled with 700 mCi/
ml of [35S]-Express label (1100 Ci/mmol; PerkinElmer, Boston,
MA) at 37uC and chased with complete DMEM supplemented
with 1 mM non-radioactive methionine and cysteine for indicated
times at 37uC. Cells were washed with PBS then lysed in Triton X-
100 lysis buffer (10 mM Tris-HCl [pH 7.4], 150 mM NaCl,
1%Triton X-100, 0.1 mM phenylmethylsufonyl fluoride (PMSF),
and 5 mM N-ethyl-maleimide (NEM)) or digitonin lysis buffer (1%
digitonin, 150 mM NaCl, 50 mM Tris-HCl [pH 7.4], 5 mM
NEM, 0.1 mM PMSF) for 5 min at 37uC to solubilize lipid rafts,
followed by rocking for 15 min at 4uC. Lysates were centrifuged
for 10 min at 16,000 X g at 4uC to pellet nuclei and debris.
Clarified lysates were incubated overnight at 4uC with designated
antibodies and Protein A agarose (Repligen Corporation,
Waltham, MA) or protein G agarose (Invitrogen). Immunopre-
cipitates were washed four times with Triton X-100 wash buffer
(10 mM Tris 7.4, 150 mM NaCl, 1%Triton X-100) or digitonin
wash buffer (0.1% digitonin, 150 mM NaCl, 50 mM Tris pH 7.4),
and subjected to SDS-PAGE gel electrophoresis. When indicated,
lysosomal inhibitors leupeptin (Sigma) and folimycin (EMD, San
Diego, CA) were added at 200 mM and 20 nM, respectively,
during the starve, pulse, and chase.
Quantification of pulse-chase analysis
Quantification was performed from phosphorimages generated
on a Storm 820 (GE Healthcare, Piscataway, NJ) using
ImageQuantTL software. In general, when measuring the half-
life of a protein by pulse-chase analysis, the amount of protein
recovered at each time point is calculated as a percent of the
protein recovered immediately following the pulse. We used this
method to quantify the stability of MICB (Figure 8 panels B and
C). However, since immunoprecipitation of immature form of
ULBP1 immediately following the pulse is inefficient, we felt it
appropriate to normalize to the amount of mature ULBP1
recovered after the 2 hr chase (Figure 5 panel B). All values are
also corrected for background. Calculations were performed as
follows: For Figure 5, the % ULBP1= (ULBP1
6hr - bkgd)/
(ULBP1
2hr - bkgd)*100. For Figure 8, panel B %MICB=
(MICB
2hr - bkgd)/(MICB
0hr - bkgd)*100. For Figure 8, panel C
all points are normalized to the 0 hr chase point as in B). For
Figure 9, panel C, the %MICB secreted at each time point =
(MICB
supernatant - bkgd)/(MICB
lysate 0hr - bkgd)*100.
Immunoprecipitation and immunoblotting
Total cell lysates were prepared in 1% Triton X-100 lysis buffer
supplemented with 50 U/ml benzonase (Sigma), followed by the
addition of an equal volume of 2% SDS and 100 mM Tris-HCl
[pH 7.4] and continued rocking at room temperature for 15 min.
Lysates were normalized to total protein concentration as
determined by BCA assay (Pierce, Rockford, IL). For immunoblot
analysis of secreted MICB, supernatants were collected and
concentrated 10 fold using a micron 30 filter (Millipore, Billerica,
MA). For immunoprecipitation-immunoblot experiments, cells
were treated with 200 mM leupeptin and 20 nM folimycin for
14 hours then lysed in digitonin lysis buffer. Immunoprecipitions
were performed, washed 4 times with digitonin wash buffer, and
eluted with Laemmli buffer. Lysates and immunoprecipitates were
resolved by SDS-PAGE electrophoresis, transferred to BA-85
nitrocellulose membrane (Whatman, Florham Park, NJ) and
probed with designated primary antibodies followed by an
appropriate HRP conjugated secondary antibody (BioRad,
Hercules, CA). Bands were visualized using SuperSignal reagent
(Pierce) and quantified with an Alpha Imager (AlphaInnotech, San
Leandro, CA).
NK cytotoxicity assays
Target cells (2.5610
4) cultured in the presence of IL-2 (50 U/
ml) were mixed with various ratios of NKL cells in V-bottom 96
well plates. When indicated, human PBMCs were isolated from
blood on Ficoll-Paque (GE Healthcare) according to manufactur-
er’s instruction and used in place of NKL cells. Plates were
centrifuged for 5 min at 125 X g to pellet cells, and incubated for
3h r a t 3 7 uC. Cells were then stained with 4 mg/ml 7-
aminoactinomycin D (7-AAD)(Sigma) for 5 min and analyzed by
flow cytometry. The percentage of target cell death was calculated
as the %7-AAD-positive target cells (ZsGreen-positive) at each
effector:target ratio minus the %7-AAD-positive target cells in the
absence of NKL cells. When indicated, target cells were incubated
with 10 mg/ml blocking antibodies for 15 minutes at 37uC prior to
the addition of NKL cells. All assays were performed in triplicate
and, unless noted, the experiments shown were the average of
three independent experiments.
Supporting Information
Figure S1 Cells with higher U21 expression display
more dramatic relocalization of ULBP1 to lysosomes. (A
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labeled with antibodies directed against ULBP1 (m295) and U21.
The arrows indicate a cell expressing a high apparent level of U21,
the arrowheads indicate a cell expressing a lower apparent level of
U21, and the asterisks indicate a cell that does not appear to
express U21. (C) U373-ULBP1 cells were infected with increasing
amounts of U21 retrovirus (lanes 2-7) and selected in puromycin to
generate stable cell lines. U373 cells and cells expressing ULBP1
alone are shown in lanes 1 and 8, for comparison. Cell lysates
(20 mg) from each cell line were immunoblotted with antibodies
directed against U21, class I MHC heavy chain (HC10), ULBP1
(AF1380), or TfR. as indicated. As more U21 is expressed, the
steady-state levels of both class I heavy chains (aMHC-I) and
ULBP1 (aULBP1) are reduced. (D) As more U21 is expressed,
relocalization of ULBP1 becomes more evident. Relocalization
(appearance of puncta as depicted in panel B (arrowhead and
arrow)) was quantified in each of the six cell lines depicted in panel
C, lanes 2-7. 1000 cells were counted and scored for the presence
of ULBP1-positive punctae (n=1). Bars reflect the percentage of
cells containing ULBP1-positive punctae from each cell line.
(TIF)
Figure S2 U21 expression induces relocalization of HA-
tagged ULBP1. Immunofluorescent detection of ULBP1 in
U373 cells expressing HA-ULBP1 (A) or HA-ULBP1 and U21 (B).
Cells were labeled with an antibody directed against ULBP1
(m295) followed by an Alexa 488-conjugated secondary antibody,
as indicated.
(TIF)
Figure S3 Core, deglycosylated MICB migrates identi-
cally in MICB- and in MICB-U21-expressing cells. U373
cells expressing MICB or MICB and U21 were pulse-labeled for
15 minutes and chased for 0, 2, or 6 hours. MICB (BMO2) was
recovered from Triton X-100 lysates and treated with either Endo
H or PNGase:F. Migration positions of EndoH sensitive MICB
(MICB(s)), PNGase:F resistant MICB (MICB(r)), and deglycosy-
lated MICB (deglycos) are indicated, as are approximate
molecular weight markers (right).
(TIF)
Figure S4 Expression of U21 in K562 cells. (A) Flow
cytometric analysis of ZsGreen from K562 cells (dark gray solid),
K562 cells expressing Zs-Green (light gray solid), or K562 cells
expressing U21-IRES-ZsGreen (black line). (B) Cell lysates (30 mg)
from ZsGreen- or U21-ZsGreen-expressing K562 cells were
immunoblotted with an antibody directed against U21. A cross-
reactive polypeptide recognized by the polyclonal U21 antibody
serves as a loading control and is denoted with an asterisk.
(TIF)
Figure S5 Expression of U21 in K562 cells reduces
sensitivity to cytotoxicity mediated by human NK cells.
Target K562 cells expressing ZsGreen or U21-ZsGreen were
incubated in the presence of freshly isolated human peripheral
blood mononuclear NK effector cells at the indicated E:T ratios.
The graphs shown are single representative experiment performed
in triplicate, and the error bars indicate the standard deviation
between replicate samples (n=1).
(TIF)
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